



UBS Conference


November 2020



PRO MEDICUS (ASX:PME)

Healthcare IT company specializing in Enterprise Imaging and Radiology Information System (RIS) software.

Leading edge products, growing global presence.




















pro+medicus.net








RESULTS FY 2020








In Review **FY 2020**







FY 2020 Revenue Split









- Used in vast majority of US contracts
- Delivered as SaaS model
- Now used in RIS contracts in AUS
- Model based on transaction minimums
- Forward revenue > A\$210M/5 years*
- Upside as client examination volumes grow
- Annuity style revenue stream greater predictability







^{*} Assumes the majority of key contracts up for renewal in years 4 & 5 are renewed



- Recurring in nature
- Increased by 30% YoY
- Growth to continue for FY 2021 (FY Duke, OSU, Northwestern & others)
- Growth from existing clients (organic and M&A) plus new clients
- Further upside with adoption of new products (VISAGE 7 Open Archive and Enterprise Imaging)


























Revenue spread over the length of the contract
new accounting standards (AASB 15)



Recurring in nature ~ 10% contract value



 Will decrease as a % of total revenue as exam (transaction) revenue increases











- Highly scalable offering
- No capex (HW) SW only model
- Training & Installation charged as professional services
- Contained cost base
- High operating leverage
- Margin continues to grow as footprint increases












- PME/Visage transitioned to WFH in mid-March
- Able to operate at 100% capacity
- Sales and marketing efforts continued throughout
- "Thinness" of the technology enabled large scale remote demonstrations
- New opportunities despite COVID restrictions.





COVID-19 - Impact




- All elective imaging deferred late in March/early April
- Some regions affected more than others
- Worst affected volumes declined by up to 75%
- 2nd half April onwards steady recovery in image volumes
- Most clients now at normal volumes some >100%
- Deferred examinations still need to be done in catch-up period





VISAGE RIS







VISAGE RIS



- Long term (5 year) contracts with Primary Healthcare and I-MED, the 2 biggest radiology providers in AUS
- Combined additional revenue of \$4.4M pa once fully deployed
- HIS (Healius) rollout nearing completion
- Upside via organic and M&A growth (i-med)
- Increased market interest new opportunities
- PME undisputed market leader












Visage 7.0

Continues to be #1 in Speed, Functionality and Scalability.












- HD Breast Tomosynthesis 6 GB+
- Optoacoustic breast ultrasound 10+ GB
- Total Body PET Scan 10+ GB
- 7T MRI much larger than 3T



VISAGE IMAGING®

LEGACY TECHNOLOGY

"Compress and Send"








SOLUTION:



VISAGE 7 Streaming Technology












Transaction-based licensing model with upside

Large regional hospital system

Teaching hospital for The Ohio State College of Medicine

Implementation completed - 100% remote



NINES



- 5 year \$6 Million platform deal
- Transaction based model volumes to step up YoY
- SaaS offering based on Visage in the Cloud
- Nines team highly respected in machine learning, Al, and radiology circles
- Leveraging the power of modern Al to clinical settings
- Opens up new market segment for PME





NORTHWESTERN



- Minimum \$22 Million over 5 years
- Transaction-based licensing model with upside
- Voted in the top 10 Hospitals in North America
- Teaching hospital for the Feinberg School of Medicine
- Adds to PME growing base of Tier-1 Healthcare institutions
- Implementation scheduled for Q3 FY21





NYU LANGONE



- \$25 Million over 7 Years
- Voted in the top 10 Hospitals in North America
- Transaction based licencing model with upside
- Teaching hospital for the Grossman School of Medicine
- Implementation scheduled for Q3/Q4 FY21
- 2nd Tier 1 academic contract win in 3 months
- 7 out of the top 20 hospitals in the US have standardized on Visage





NYU LANGONE - Joint R&D



- Multi Year research collaboration agreement
- NYU to be part of the Visage Al Accelerator program
- Joint R&D to develop next generation imaging products
- Visage to have onsite access to NYU Langone radiologists and imaging scientists.
- Visage to setup new R&D hub in NYC starting July 2021
- Leverage R&D and commercialization opportunities











DER UNIVERSITÄT MÜNCHEN

- \$10M 7 year Deal
- One or Europe's largest teaching hospitals
- 2nd major hospital contract in Germany
- Visage 7 Viewer and Visage Open archive
- Breaks the mold of "one-stop-shop" modality vendor systems
- Paves the way for further European sales





FAST TRACK IMPLEMENTATION



- Fast track methodology continues to deliver
- Large scale projects completed in under 1/4 the time of industry norm
- Delivers huge savings for client
- Frees PME staff for other jobs
- Reduces barrier to change
- OSU first 100% remote implementation
- A key differentiator of Visage offering





VISAGE - PROVEN ROI





Significant IT & Infrastructure Savings



Unparalleled Increase in Radiologist Efficiency



Greater Clinical Accuracy



Improved Physician Engagement



Delivers Superior Value Proposition



















GROWTH STRATEGY



NORTH AMERICAN PIPELINE








NEW PRODUCTS

- Same highly scalable enterprise imaging platform used in VISAGE 7
- Interoperable works in complex environments
- Enables Visage to offer choice of modular or single vendor solutions
- Pipeline includes opportunities for Viewer and Visage Open Archive
- Well placed for North American archive market

VISAGE 7 OPEN ARCHIVE












NEW PRODUCTS

- Single viewer for ALL images in the medical record (EMR)
- Radiology/Cardiology (DICOM format)
- Non-radiology- reflected light hi-res photos & videos
- VISAGE 7 technology ideally suited
- Increases Visage value proposition
- Growth opportunities within existing contracts

ENTERPRISE IMAGING









- Adds to V7 Viewer and Archive modules
- Based on over 30 years experience in Worklist SW
- Allows PME to offer single vendor solution if required
- Integral part of Visage in the Cloud SaaS solution
- Ability to interface with broad range of Al algorithms







CTA HEAD A Emero

CT ANGIO AI Int





- Same ultrafast performance as on premise
- Full Visage 7 functionality
- Security and scale of the cloud
- Full deployment or as backup/disaster recovery
- Suitable for all size implementations
- Opens up new market opportunities





Visage 7

- Unique end to end solution
- Supports both research and production environments on a single platform
- Based on market leading Visage 7 technology
- Enables Visage clients to fast track Al as part of their imaging strategy





Visage 7



- Optimised for AI data curation and validation
- Open API seamless integration
- Al Ecosystem 3rd party and Visage developed algorithms
- Joint development/commercialisation opportunities – 3rd parties and academic clients.





Al Research Leadership




Malte Westerhoff Chief Technology Officer



Detlev Stalling Head of Development









Breast Density - Al



- Developed in collaboration with renown breast imaging team at Yale
- Provides "on the fly" Al assessment of breast density
- Previewed at RSNA 2019 as WIP
- Pending FDA approval
- A model for future collaboration with other academic institutions






SUMMARY

- Growing North American footprint
- Transaction revenue up 30% YoY
- Market leading technologies
- Growing product portfolio
- Proven implementation & support capability
- Unparalleled value proposition (Clinical and Financial ROI)
- Pipeline Continues to grow strongly.
- Visage Al-Accelerator strategically positioned to leverage Al







THANK YOU



